Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Why should I use sharewise

Clovis Oncology Inc. Stock

Price
Target price
€6.51

€6.51

30.610%
1.668
30.610%
€9.00

€9.00

 
Latest predictions
€5.00
24.03.20
buy
€6.00
22.03.20
buy
-
26.01.20
€12.00
18.01.20
buy
-
25.11.19
buy
-
24.11.19
buy
Your prediction

Clovis Oncology Inc. Stock

A very strong showing by Clovis Oncology Inc. today, with an increase of €1.67 (30.610%) compared to yesterday's price.
We see a rather positive sentiment for Clovis Oncology Inc. with 6 Buy predictions and 1 Sell predictions.
With a target price of €9.00 there is a positive potential of 38.185% for Clovis Oncology Inc. compared to the current price of €6.51.
Register To Post

Other discussions about Clovis Oncology Inc. Stock

New thread

News

Clovis Oncology to Present at the Barclays Global Healthcare Conference


Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Barclays Global Healthcare Conference on Tuesday, March

Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Spain


Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca® (rucaparib) is now available and reimbursed in Spain following the Spanish Interministerial Commission on Prices of Medicines and

Clovis Oncology Announces 2019 Operating Results


Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2019, and provided an update on Clovis’ clinical development programs and regulatory and

Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24


Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2019 financial results on Monday, February 24, 2020, after the close of the U.S. financial markets. Clovis’

Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference


Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 9th Annual SVB Leerink Global Healthcare Conference on

Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France


Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca® (rucaparib) is now available and reimbursed in France. Rubraca® (rucaparib) is an option for monotherapy maintenance treatment for

Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer


Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for Rubraca® (rucaparib)

Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019


Clovis
Oncology
, Inc. (NASDAQ:CLVS) today announced its preliminary,
unaudited revenues for the fourth quarter and full year ended December
31, 2019. The financial

Clovis Oncology Announces Debt Refinancing Transaction


Clovis Oncology, Inc. (NASDAQ: CLVS) (the “Company”) announced today that on January 6, 2020 it priced a registered direct offering (the “Share Offering”) of an aggregate of 17,777,679 shares (the

Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium


Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that Professor Dr. Richard P. Baum reported his initial independent clinical experience with FAP-2286 in named-patient use at the International

Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy


Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the Italian Medicines Agency (AIFA) has approved rucaparib for reimbursement in Italy. Rucaparib will soon be available as an option for

Clovis Oncology Announces Third Quarter 2019 Operating Results


Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2019, and provided an update on Clovis’ clinical development programs and regulatory and